Insider Selling: Heartflow (NASDAQ:HTFL) Insider Sells $1,316,554.33 in Stock

Heartflow, Inc. (NASDAQ:HTFL) insider Campbell Rogers sold 23,933 shares of the company’s stock in a transaction that occurred on Thursday, October 22nd. The shares were sold at an average price of $55.01, for a total value of $1,316,554.33. Following the transaction, the insider directly owned 73,453 shares of the company’s stock, valued at $4,040,649.53. This trade represents a 24.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Campbell Rogers also recently made the following trade(s):

• On Friday, September 18th, Campbell Rogers sold 19,682 shares of Heartflow stock. The stock was sold at an average price of $50.15, for a total value of $987,052.30.
• On Monday, August 17th, Campbell Rogers sold 9,219 shares of Heartflow stock. The shares were sold at an average price of $41.23, for a total value of $380,099.37.

Heartflow Price Performance

HTFL traded up $0.30 during trading on Monday, reaching $57.01. 1,058,656 shares of the company were exchanged, compared to its average volume of 1,655,511. Heartflow, Inc. has a 52 week low of $20.13 and a 52 week high of $57.74. The firm has a 50 day moving average of $49.38 and a 200 day moving average of $33.51.

Heartflow (NASDAQ:HTFL) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The company had revenue of $64.08 million for the quarter. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. On average, research analysts forecast that Heartflow, Inc. will post -0.75 earnings per share for the current year.

Hedge Funds Weigh In On Heartflow

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. XXEC Inc. bought a new stake in shares of Heartflow in the 2nd quarter worth $2,524,764,000. BlackRock Inc. bought a new position in Heartflow during the second quarter valued at about $152,502,000. Bamco Inc. NY bought a new position in Heartflow during the second quarter valued at about $94,625,000. Jupiter Topco LLC acquired a new position in Heartflow during the second quarter worth about $70,983,000. Finally, Janus Henderson Group PLC grew its holdings in Heartflow by 152.0% during the first quarter. Janus Henderson Group PLC now owns 2,180,976 shares of the company’s stock worth $53,063,000 after acquiring an additional 1,315,416 shares during the period.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on HTFL. Robert W. Baird set a $45.00 price target on Heartflow in a research note on Friday, August 14th. Canaccord Genuity Group lifted their price objective on shares of Heartflow from $45.00 to $56.00 and gave the company a “buy” rating in a research note on Tuesday, September 22nd. Benchmark reaffirmed a “buy” rating on shares of Heartflow in a report on Friday, August 14th. Wall Street Zen upgraded shares of Heartflow from a “hold” rating to a “buy” rating in a research report on Sunday. Finally, UBS Group initiated coverage on shares of Heartflow in a research note on Wednesday, September 9th. They set a “neutral” rating and a $55.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Heartflow currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.62.

Heartflow Company Profile

Heartflow, Inc is a medical technology company that develops artificial intelligence-based tools to help physicians diagnose and manage coronary artery disease. Its platform uses data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient’s coronary arteries and provide noninvasive assessments of blood flow and disease.

The company’s products include Heartflow Analysis, which provides fractional flow reserve computed tomography (FFR-CT) evaluations to help identify potentially significant blockages, as well as tools for assessing coronary plaque and planning treatment.